MDS with TP53 mutation (mono- or biallelic) — distinct WHO 5th-ed entity with poor outcom...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

ID	`RF-MDS-TP53-MUTATION`
Type	Signal d’alerte
État	reviewed 2026-04-25 \| pending_clinical_signoff
Maladies	`DIS-MDS-HR` `DIS-MDS-LR`
Sources	`SRC-ESMO-MDS-2021` `SRC-IPSS-M-BERNARD-2022` `SRC-NCCN-AML-2025`

Origine du drapeau rouge

Définition	MDS with TP53 mutation (mono- or biallelic) — distinct WHO 5th-ed entity with poor outcomes on HMA monotherapy and reduced alloHCT benefit; consideration of intensified / experimental therapy or palliative intent
Direction clinique	intensifier
Catégorie	high-risk-biology
Algorithme de décalage	ALGO-MDS-HR-1L

Logique de déclenchement

{
  "any_of": [
    {
      "finding": "tp53_mutation",
      "value": true
    },
    {
      "finding": "tp53_biallelic",
      "value": true
    },
    {
      "finding": "del_17p",
      "value": true
    },
    {
      "comparator": ">=",
      "finding": "tp53_vaf_pct",
      "threshold": 10
    }
  ],
  "type": "biomarker"
}

Notes

TP53-mutated MDS is its own WHO 5th-edition entity with median OS ~6-9 months on standard HMA. AlloHCT carries higher relapse risk vs TP53-wt. Active research questions: ven+aza vs aza alone, magrolimab + aza (failed phase-3 ENHANCE), eprenetapopt + aza (mixed results). NOT clear best regimen — flagged as intensify but the algorithm should also surface palliative-intent option. STUB — requires clinical co-lead signoff.

Utilisé par

Algorithmes

ALGO-MDS-HR-1L - ALGO-MDS-HR-1L
ALGO-MDS-HR-2L - ALGO-MDS-HR-2L

Biomarqueur

BIO-AML-TP53-ADVERSE - TP53-mutated AML (adverse risk)

Indication

IND-MDS-HR-1L-AZA - IND-MDS-HR-1L-AZA
IND-MDS-HR-ALLOHCT - IND-MDS-HR-ALLOHCT
IND-MDS-LR-LENALIDOMIDE-DEL5Q - IND-MDS-LR-LENALIDOMIDE-DEL5Q

Signal d’alerte

RF-AML-TP53-ADVERSE - TP53-mutated AML — ELN-2022 adverse-risk classifier and WHO 5th- edition entity. ~10-15%...